Elicio Therapeutics (ELTX) Operating Leases (2020 - 2026)

Elicio Therapeutics has reported Operating Leases for 7 years, with the latest figure at $3.8 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 33.98% year-over-year to $3.8 million; the trailing twelve-month figure through Mar 2026 stood at $3.8 million (down 33.98% YoY), and the FY2025 full-year result was $4.1 million, down 19.8% from the prior year.
• Operating Leases for Q1 2026 stood at $3.8 million, down from $4.1 million in the prior quarter.
• The five-year high for Operating Leases was $7.4 million in Q2 2023, with the low at $297000.0 in Q1 2023.
• Historically, Operating Leases has averaged $4.8 million across 5 years, with a median of $5.3 million in 2025.
• Annual changes were most pronounced in 2023 — Operating Leases plunged 90.82% — and 2024, when it jumped 1849.83%.
• Elicio Therapeutics' Operating Leases stood at $6.8 million in 2022, then dropped by 11.52% to $6.0 million in 2023, then declined by 15.02% to $5.1 million in 2024, then retreated by 19.8% to $4.1 million in 2025, then decreased by 6.62% to $3.8 million in 2026.
• The last three Operating Leases figures came in at $3.8 million (Q1 2026), $4.1 million (Q4 2025), and $5.3 million (Q3 2025), per Business Quant data.